COVID-19 Pharmaceuticals Public Policy

Reference pricing in the US for COVID drugs?

Perhaps according to a report from Stat News:

A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.
The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

To get up to speed on reference pricing, see my previous posts on the topic: